Mutant P53(L194f) Harboring Luminal-A Breast Cancer Cells Are Refractory To Apoptosis And Cell Cycle Arrest In Response To Mortaparib(Plus), A Multimodal Small Molecule Inhibitor

Simple Summary Tumor suppressor protein p53 is a master regulator that inhibits the process of oncogenesis by induction of cell senescence/cell cycle arrest/apoptosis during normal and stressed states of cells. It is functionally inactivated in the majority of cancers. Mortalin, a member of the Hsp70 family of proteins, enriched in cancer cells, is known to cause cytoplasmic sequestration and inactivation of the p53's transcriptional activation function. Inhibition of mortalin-p53 interaction and reactivation of p53 functions by natural and synthetic drugs has emerged as a possible cancer therapeutic strategy. We recently reported a novel multimodal small molecule, named Mortaparib(Plus), that inhibited mortalin-p53 interaction and caused reactivation of p53 function in colorectal cancer cells. Here, we report its effect on breast cancer cells with wildtype (MCF-7) or mutant (T47D) p53 status. We previously performed a drug screening to identify a potential inhibitor of mortalin-p53 interaction. In four rounds of screenings based on the shift in mortalin immunostaining pattern from perinuclear to pan-cytoplasmic and nuclear enrichment of p53, we had identified Mortaparib(Plus) (4-[(1E)-2-(2-phenylindol-3-yl)-1-azavinyl]-1,2,4-triazole) as a novel synthetic small molecule. In order to validate its activity and mechanism of action, we recruited Luminal-A breast cancer cells, MCF-7 (p53(wild type)) and T47D (p53(L194F)) and performed extensive biochemical and immunocytochemical analyses. Molecular analyses revealed that Mortaparib(Plus) is capable of abrogating mortalin-p53 interaction in both MCF-7 and T47D cells. Intriguingly, upregulation of transcriptional activation function of p53 (as marked by upregulation of the p53 effector gene-p21(WAF1)-responsible for cell cycle arrest and apoptosis) was recorded only in Mortaparib(Plus)-treated MCF-7 cells. On the other hand, Mortaparib(Plus)-treated T47D cells exhibited hyperactivation of PARP1 (accumulation of PAR polymer and decrease in ATP levels) as a possible non-p53 tumor suppression program. However, these cells did not show full signs of either apoptosis or PAR-Thanatos. Molecular analyses attributed such a response to the inability of Mortaparib(Plus) to disrupt the AIF-mortalin complexes; hence, AIF did not translocate to the nucleus to induce chromatinolysis and DNA degradation. These data suggested that the cancer cells possessing enriched levels of such complexes may not respond to Mortaparib(Plus). Taken together, we report the multimodal anticancer potential of Mortaparib(Plus) that warrants further attention in laboratory and clinical studies.